The Potential of BRD4 Inhibition in Tumour Mechanosignaling

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2023 Nov 23

PMID 37994501

Authors

Antonios N Gargalionis

Kostas A Papavassiliou

Athanasios G Papavassiliou

Affiliations

Soon will be listed here.

Citing Articles

Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.

Piombino C, Pipitone S, Tonni E, Mastrodomenico L, Oltrecolli M, Tchawa C Int J Mol Sci. 2024; 25(9).

PMID: 38731844 PMC: 11083429. DOI: 10.3390/ijms25094624.

The potential of BRD4 inhibition in tumour mechanosignaling.

Gargalionis A, Papavassiliou K, Papavassiliou A J Cell Mol Med. 2023; 27(24):4215-4218.

PMID: 37994501 PMC: 10746939. DOI: 10.1111/jcmm.18057.

References

Zanconato F, Battilana G, Forcato M, Filippi L, Azzolin L, Manfrin A . Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. Nat Med. 2018; 24(10):1599-1610. PMC: 6181206. DOI: 10.1038/s41591-018-0158-8. View

Battilana G, Zanconato F, Piccolo S . Mechanisms of YAP/TAZ transcriptional control. Cell Stress. 2021; 5(11):167-172. PMC: 8561301. DOI: 10.15698/cst2021.11.258. View

Shi Y, Fu Y, Zhang X, Zhao G, Yao Y, Guo Y . Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother. 2020; 70(1):61-73. PMC: 7838139. DOI: 10.1007/s00262-020-02653-1. View

Shorstova T, Foulkes W, Witcher M . Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer. 2021; 124(9):1478-1490. PMC: 8076232. DOI: 10.1038/s41416-021-01321-0. View

Song J, Dang X, Shen X, Liu Y, Gu J, Peng X . The YAP-TEAD4 complex promotes tumor lymphangiogenesis by transcriptionally upregulating CCBE1 in colorectal cancer. J Biol Chem. 2023; 299(4):103012. PMC: 10124907. DOI: 10.1016/j.jbc.2023.103012. View

Nicholls S, Schwartz G, Buhr K, Ginsberg H, Johansson J, Kalantar-Zadeh K . Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021; 20(1):13. PMC: 7791841. DOI: 10.1186/s12933-020-01199-x. View

Alam J, Huda M, Tackett A, Miah S . Oncogenic signaling-mediated regulation of chromatin during tumorigenesis. Cancer Metastasis Rev. 2023; 42(2):409-425. PMC: 10348982. DOI: 10.1007/s10555-023-10104-3. View

Dawson M, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A . A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2022; 29(4):711-722. PMC: 9932578. DOI: 10.1158/1078-0432.CCR-22-1284. View

Zhang G, Huang S, Ye L, Liu X, Shi W, Ren Z . Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Pharmacol Res. 2022; 184:106464. DOI: 10.1016/j.phrs.2022.106464. View

10.

Gargalionis A, Papavassiliou K, Papavassiliou A . The potential of BRD4 inhibition in tumour mechanosignaling. J Cell Mol Med. 2023; 27(24):4215-4218. PMC: 10746939. DOI: 10.1111/jcmm.18057. View

11.

Song S, Li Y, Xu Y, Ma L, Pizzi M, Jin J . Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Mol Oncol. 2020; 14(6):1410-1426. PMC: 7266288. DOI: 10.1002/1878-0261.12667. View

12.

Blum K, Supko J, Maris M, Flinn I, Goy A, Younes A . A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer Res Commun. 2023; 2(8):795-805. PMC: 10010313. DOI: 10.1158/2767-9764.CRC-22-0060. View

13.

Houzelstein D, Bullock S, Lynch D, Grigorieva E, Wilson V, Beddington R . Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol Cell Biol. 2002; 22(11):3794-802. PMC: 133820. DOI: 10.1128/MCB.22.11.3794-3802.2002. View

14.

Gargalionis A, Papavassiliou K, Papavassiliou A . Targeting the YAP/TAZ mechanotransducers in solid tumour therapeutics. J Cell Mol Med. 2023; 27(13):1911-1914. PMC: 10315712. DOI: 10.1111/jcmm.17794. View

15.

Gargalionis A, Basdra E, Papavassiliou A . Mechanosignalling in tumour progression. J Cell Mol Med. 2017; 22(2):704-705. PMC: 5783856. DOI: 10.1111/jcmm.13452. View

16.

Aggarwal R, Schweizer M, Nanus D, Pantuck A, Heath E, Campeau E . A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020; 26(20):5338-5347. PMC: 7572827. DOI: 10.1158/1078-0432.CCR-20-1707. View

17.

Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M . Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474(7350):179-83. DOI: 10.1038/nature10137. View

18.

Lewin J, Soria J, Stathis A, Delord J, Peters S, Awada A . Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. J Clin Oncol. 2018; 36(30):3007-3014. DOI: 10.1200/JCO.2018.78.2292. View

19.

Wu D, Qiu Y, Jiao Y, Qiu Z, Liu D . Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy. Front Oncol. 2020; 10:560487. PMC: 7686570. DOI: 10.3389/fonc.2020.560487. View

20.

Cousin S, Blay J, Garcia I, de Bono J, Le Tourneau C, Moreno V . Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. Int J Cancer. 2021; 150(6):993-1006. DOI: 10.1002/ijc.33861. View